Literature DB >> 7587959

Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.

F Innocenti1, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci, M Del Tacca.   

Abstract

The pharmacokinetics of single intraperitoneal doses of paclitaxel (18 and 36 mg/kg) in mice were investigated in the present study. The analysis of drug concentrations by HPLC indicated that the plasma Cmax (13.0 +/- 3.1 and 25.7 +/- 2.8 micrograms/ml, respectively) were reached at the 2nd hr. The values of CL were low (0.06 and 0.1 ml/min, respectively), and t1/2 beta values of 3.0 and 3.7 hr were found, after 18 and 36 mg/kg, respectively. The highest tissue concentrations were observed in the liver (50.2 +/- 3.1 and 92.0 +/- 9.5 micrograms/g respectively), followed by the pancreas (39.3 +/- 9.9 micrograms/g) and the ovary (53.4 +/- 5.6 micrograms/g) after 18 and 36 mg/kg, respectively. In the case of the colic tissue, paclitaxel Cmax were 14.4 +/- 0.8 and 32.8 +/- 3.5 micrograms/g at the 3rd hr, respectively, with sustained drug levels still detectable 24 hr after treatment. Paclitaxel Cmax values of 12.7 +/- 3.0 and 53.4 +/- 5.6 micrograms/g were detected in the ovary after 18 and 36 mg/kg, respectively. The overall results provide evidence that, after intraperitoneal administration, paclitaxel concentrates in peritoneal organs; however, the intraperitoneal route does not prevent systemic drug exposure, allowing high and sustained levels of paclitaxel also in several extraperitoneal tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587959

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  p53-independent apoptosis induced by paclitaxel through an indirect mechanism.

Authors:  J S Lanni; S W Lowe; E J Licitra; J O Liu; T Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

3.  Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.

Authors:  Neha N Parayath; Srujan Kumar Gandham; Fraser Leslie; Mansoor M Amiji
Journal:  Cancer Lett       Date:  2019-07-06       Impact factor: 8.679

4.  Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model.

Authors:  Ming Yang; Tao Yu; Joseph Wood; Ying-Ying Wang; Benjamin C Tang; Qi Zeng; Brian W Simons; Jie Fu; Chi-Mu Chuang; Samuel K Lai; T-C Wu; Chien-Fu Hung; Justin Hanes
Journal:  Drug Deliv Transl Res       Date:  2014-04-01       Impact factor: 4.617

Review 5.  Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle.

Authors:  Aaron H Colby; Nicholas H Oberlies; Cedric J Pearce; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-09

6.  Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis.

Authors:  Victoria Lm Herrera; Aaron H Colby; Glaiza Al Tan; Ann M Moran; Michael J O'Brien; Yolonda L Colson; Nelson Ruiz-Opazo; Mark W Grinstaff
Journal:  Nanomedicine (Lond)       Date:  2016-04-14       Impact factor: 5.307

7.  Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing.

Authors:  Juan F Granada; Mark Stenoien; Piotr P Buszman; Armando Tellez; Dan Langanki; Greg L Kaluza; Martin B Leon; William Gray; Michael R Jaff; Robert S Schwartz
Journal:  Open Heart       Date:  2014-08-06

8.  Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.

Authors:  Fabian Müller; Stephanie Stookey; Tyler Cunningham; Ira Pastan
Journal:  Oncotarget       Date:  2017-05-09

9.  Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.

Authors:  Aaron H Colby; Rong Liu; Morgan D Schulz; Robert F Padera; Yolonda L Colson; Mark W Grinstaff
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

10.  Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach.

Authors:  Madeleine Benguigui; Dror Alishekevitz; Michael Timaner; Dvir Shechter; Ziv Raviv; Sebastien Benzekry; Yuval Shaked
Journal:  Oncotarget       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.